Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required

Rhea-AI Summary

Evofem Biosciences has secured improved coverage for its hormone-free contraceptive Phexxi in New York, benefiting over 5.8 million lives. This update follows the state's transition to a single Preferred Drug List as of April 1, 2023, which eliminates the need for Prior Authorization. Year-to-date, Evofem has successfully gained coverage for a total of 22.1 million lives nationally. In Q1 2023, enhancements included coverage from Mississippi Medicaid, Indiana State Medicaid, and notable Blue Cross Blue Shield plans, among others. Phexxi serves as an innovative solution in women's reproductive health, applied just before sexual activity.

Positive

• Improved coverage for Phexxi benefits over 5.8 million lives in New York.
• Year-to-date coverage gained for Phexxi exceeds 22.1 million lives.
• New York Medicaid's Preferred Drug List simplifies access with no Prior Authorization.

Negative

• None.

— Improves Phexxi coverage for more than 5.8 million New York lives —

— Year-to-date, Evofem has gained Phexxi coverage for more than 22.1 million new lives —

SAN DIEGO, April 12, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced a major new win in New York state that improves coverage for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free contraceptive vaginal gel, for more than 5.8 million lives statewide.

New York Medicaid transitioned to a single Preferred Drug List effective April 1, 2023, that includes no Prior Authorization requirement on Phexxi. This facilitates access to Phexxi for women covered by New York Medicaid, the largest of all Commercial and Medicaid payers in New York.

In the first quarter of 2023, Evofem gained Phexxi coverage for 16.3 million new lives from payers including Mississippi Medicaid, Indiana State Medicaid, multiple Blue Cross Blue Shield plans, and the largest commercial payer in Michigan.

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-wins-phexxi-coverage-with-largest-payer-in-new-york-with-no-prior-authorization-required-301795517.html

SOURCE Evofem Biosciences, Inc.

FAQ

What recent coverage change did Evofem announce for Phexxi?

Evofem announced improved coverage for Phexxi benefiting over 5.8 million lives in New York due to the state's new Preferred Drug List effective April 1, 2023.

How many new lives has Evofem gained coverage for Phexxi in 2023?

In 2023, Evofem has gained coverage for Phexxi for more than 22.1 million new lives.

What does the new coverage for Phexxi in New York mean for patients?

The new coverage means women covered by New York Medicaid can access Phexxi without a Prior Authorization requirement, improving accessibility.

When did New York Medicaid transition to the new Preferred Drug List?

The transition to a single Preferred Drug List by New York Medicaid took effect on April 1, 2023.